Celyad Oncology SA

2.06+0.0300+1.48%Vol 22.16K1Y Perf -50.61%
Aug 11th, 2022 13:48 DELAYED
BID2.00 ASK2.12
Open2.12 Previous Close2.03
Pre-Market- After-Market-
 - -  - -%
Target Price
11.00 
Analyst Rating
Strong Buy 1.00
Potential %
433.98 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     46.41
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     44.54
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
14.44 
Earnings Rating
Neutral
Market Cap46.54M 
Earnings Date
5th Aug 2022
Alpha-0.05 Standard Deviation0.16
Beta1.38 

Today's Price Range

2.002.12

52W Range

1.515.32

5 Year PE Ratio Range

-6.70-5.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-15.57%
1 Month
24.85%
3 Months
22.43%
6 Months
-40.46%
1 Year
-50.61%
3 Years
-83.52%
5 Years
-95.10%
10 Years
-

TickerPriceChg.Chg.%
CYAD2.060.03001.48
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
100.00
-263 946.00
-247 654.00
-180 441.00
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-87.15
67.90
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
6/2019 QR-1.5810.73Positive
12/2019 QR-1.65-0.61Negative
12/2022 FY-1.043.70Positive
12/2023 FY-0.942.08Positive
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume22.16K
Shares Outstanding22.59K
Shares Float22.59M
Trades Count82
Dollar Volume46.10K
Avg. Volume235.80K
Avg. Weekly Volume97.42K
Avg. Monthly Volume448.71K
Avg. Quarterly Volume161.27K

Celyad Oncology SA (NASDAQ: CYAD) stock closed at 2.06 per share at the end of the most recent trading day (a 1.48% change compared to the prior day closing price) with a volume of 22.16K shares and market capitalization of 46.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 107 people. Celyad Oncology SA CEO is Filippo Petti.

The one-year performance of Celyad Oncology SA stock is -50.61%, while year-to-date (YTD) performance is -43.72%. CYAD stock has a five-year performance of -95.1%. Its 52-week range is between 1.51 and 5.32, which gives CYAD stock a 52-week price range ratio of 14.44%

Celyad Oncology SA currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 0.99, a price-to-sale (PS) ratio of 435 018.00, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -38.66%, a ROC of -74.51% and a ROE of -82.13%. The company’s profit margin is -%, its EBITDA margin is -247 654.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Celyad Oncology SA, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Celyad Oncology SA’s next earnings report date is -.

The consensus rating of Wall Street analysts for Celyad Oncology SA is Strong Buy (1), with a target price of $11, which is +433.98% compared to the current price. The earnings rating for Celyad Oncology SA stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Celyad Oncology SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Celyad Oncology SA has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.17, ATR14 : 0.24, CCI20 : 43.64, Chaikin Money Flow : 0.34, MACD : 0.08, Money Flow Index : 92.05, ROC : 17.71, RSI : 51.73, STOCH (14,3) : 38.89, STOCH RSI : 0.28, UO : 46.43, Williams %R : -61.11), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Celyad Oncology SA in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (33.33 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Moderate Buy
1.67
Moderate Buy
1.67

Celyad Oncology SA

Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

CEO: Filippo Petti

Telephone: +32 10394100

Address: Rue Edouard Belin 2, Mont-Saint-Guibert 1435, , BE

Number of employees: 107

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

50%50%

Bearish Bullish

51%49%

TipRanks News for CYAD

Mon, 28 Feb 2022 16:39 GMT Celyad (CYAD) Receives a Hold from JonesTrading

- TipRanks. All rights reserved.

Mon, 28 Feb 2022 15:45 GMT Celyad (CYAD) was Downgraded to a Hold Rating at H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits